20240034727. IMIDAZOLE COMPOUNDS AS INHIBITORS OF ENPP1 simplified abstract (STINGRAY THERAPEUTICS, INC.)
Contents
IMIDAZOLE COMPOUNDS AS INHIBITORS OF ENPP1
Organization Name
Inventor(s)
Srinivas Rao Kasibhatla of San Diego CA (US)
Sunil Sharma of Phoenix AZ (US)
Mohan Kaadige of Scottsdale AZ (US)
Alexis Weston of Phoenix AZ (US)
Trason Thode of Phoenix AZ (US)
IMIDAZOLE COMPOUNDS AS INHIBITORS OF ENPP1 - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240034727 titled 'IMIDAZOLE COMPOUNDS AS INHIBITORS OF ENPP1
Simplified Explanation
The abstract of the patent application describes compounds that act as inhibitors of ENPP1, a protein associated with disorders such as uncontrolled cellular proliferation, cancer, and viral or bacterial infections. The compounds have a specific chemical structure and can exist as salts, tautomers, stereoisomers, or prodrugs. The patent application provides methods for preparing and using these compounds, as well as pharmaceutical compositions containing them.
- The patent application describes compounds that inhibit the activity of ENPP1.
- The compounds have a specific chemical structure represented by structure (i).
- The compounds can exist as salts, tautomers, stereoisomers, or prodrugs.
- The patent application provides methods for preparing and using these compounds.
- The compounds can be used in pharmaceutical compositions for treating disorders associated with ENPP1.
- The disorders include uncontrolled cellular proliferation, cancer, and viral or bacterial infections.
Potential Applications:
- Treatment of disorders associated with ENPP1, such as uncontrolled cellular proliferation, cancer, and viral or bacterial infections.
- Development of pharmaceutical compositions containing the compounds as active ingredients.
Problems Solved:
- Inhibition of ENPP1 activity, which is associated with disorders such as uncontrolled cellular proliferation, cancer, and viral or bacterial infections.
- Providing a method for preparing and using compounds that can effectively inhibit ENPP1.
Benefits:
- Potential treatment options for disorders associated with ENPP1.
- Development of new pharmaceutical compositions with improved efficacy in treating uncontrolled cellular proliferation, cancer, and viral or bacterial infections.
Original Abstract Submitted
compounds having activity as inhibitors of enpp1 are provided. the compounds have the following structure (i): or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof, wherein l, r, r, r, r, r, rand n are as defined herein. this disclosure provides methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds, and methods for treating disorders associated with enpp1, including uncontrolled cellular proliferation, cancer and virial or bacterial infections in a mammal.
